Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism prophylaxis: a systematic review of efficacy, safety, and cost-effectiveness.

Front Pharmacol · 2025 · PMC12507576 · PMID 41079743

Europe PMC DOI

hedged sentence

0.6020

closest p · 12.0× alpha

0.6020

boldest claim

The sentences

showed a trendp = 0.602not close (p > 0.1)

Similarly, a retrospective cohort study of 296 cancer patients with VTE showed a trend toward lower mortality in the rivaroxaban group (8.0% vs. 10.0%, p = 0.602) ( Dong et al., 2024 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.